Evidence map›Paper›PMID 30650380›Full record

ReviewImmunity2019

Plasmacytoid Dendritic Cells: Development, Regulation, and Function.

Boris Reizis

Open access · bronzeAbstract readReview
In one paragraph

Review in Immunity, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 412 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
412citing papers in PubMed, 1 pooled it
23.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

412 citing papers in PubMed, 1 synthesis or guideline pooled it, 624 citations in OpenAlex.

  1. Frontiers in immunology · 2025
    Pooled it
  2. Trial
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Review
  10. Review
  11. Article
  12. Review
  13. Review
  14. Review
  15. Suggestive characteristic change of CD123Journal of clinical and experimental hematopathology : JCEH · 2026
    Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article

352 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Boris ReizisDepartment of Pathology and Department of Medicine, New York University School of Medicine, New York, NY 10016, USA. Electronic address: boris.reizis@nyumc.org.
New York University · US

Funding

Viral Assays CoreU19AI128949 · NIAID · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI Peter Alan Sims · 2017 to 2026
$26.4M
Molecular Control of Plasmacytoid Dendritic Cell Development and FunctionR37AI072571 · NIAID · UNIVERSITY OF CHICAGO · PI Boris Reizis · 2018 to 2026
$5.3M
Molecular Control of Plasmacytoid Dendritic Cell Development and FunctionR01AI072571 · NIAID · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI REIZIS, BORIS · 2008 to 2017
$4.1M
NIAID NIH HHS R01 AI072571NIAID NIH HHS R37 AI072571NIAID NIH HHS U19 AI128949
6 · The paper itself

Abstract

Plasmacytoid dendritic cells (pDCs) are a unique sentinel cell type that can detect pathogen-derived nucleic acids and respond with rapid and massive production of type I interferon. This review summarizes our current understanding of pDC biology, including transcriptional regulation, heterogeneity, role in antiviral immune responses, and involvement in immune pathology, particularly in autoimmune diseases, immunodeficiency, and cancer. We also highlight the remaining gaps in our knowledge and important questions for the field, such as the molecular basis of unique interferon-producing capacity of pDCs. A better understanding of cell type-specific positive and negative control of pDC function should pave the way for translational applications focused on this immune cell type.

Indexed as

Cell DifferentiationAnimalsAutoimmune DiseasesDendritic CellsGene Expression RegulationHumansImmunity, CellularInterferon Type INeoplasmsVirus DiseasesInterferon Type IPlasmacytoid dendritic cells (pDCs) are innate immune sentinels that play important roles in immunity to infection and autoimmunity. This review by Boris Reizis highlights recent progress and emerging areas of interest in pDC biology as well as translational applications

Identifiers

PMID30650380
PMCPMC6342491
OpenAlexW2908943028

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.